{"id":840168,"date":"2026-09-03T21:49:29","date_gmt":"2026-09-03T13:49:29","guid":{"rendered":"https:\/\/www.alphaseek.cn\/?p=840168"},"modified":"2026-09-03T21:49:29","modified_gmt":"2026-09-03T13:49:29","slug":"%e7%be%8e%e8%82%a1%e8%b7%8c%e5%b9%85%e6%a6%9c%e5%89%8d%e5%8d%81%ef%bc%8cultragenyx-pharmaceutical-inc-rare-us%e8%b7%8c44-89%ef%bc%8cgix-internet-ltd-gixi-us%e8%b7%8c41-50","status":"publish","type":"post","link":"https:\/\/www.alphaseek.cn\/?p=840168","title":{"rendered":"\u7f8e\u80a1\u8dcc\u5e45\u699c\u524d\u5341\uff0cUltragenyx Pharmaceutical, Inc.(RARE.US)\u8dcc44.89%\uff0cGix Internet Ltd.(GIXI.US)\u8dcc41.50%"},"content":{"rendered":"
\n
\n
\n
<\/i><\/a> <\/div>\n
\n
\n
\u65e5\u671f\uff1a<\/span> 2026\u5e749\u67083\u65e5 \u4e0b\u53489:45<\/span> <\/div>\n<\/p><\/div>\n
<\/i><\/a><\/i><\/a><\/p>\n
<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n
<\/div>\n
\n

\u3010\u8ca1\u83ef\u793e\u8a0a\u3011\u5317\u4eac\u6642\u95932026\u5e749\u670803\u65e5\u665a\u9593\uff0c\u7f8e\u80a1\u5468\u56db\u65e9\u76e4\uff0c\u7f8e\u80a1\u8dcc\u5e45\u699c\u524d\u5341\u540d\u5206\u5225\u70baUltragenyx Pharmaceutical, Inc.(RARE.US)\u8dcc\u5e4544.89%\u3001Gix Internet Ltd.(GIXI.US)\u8dcc\u5e4541.50%\u3001Medicus Pharma Ltd(MDCX.US)\u8dcc\u5e4530.70%\u3001Advasa Holdings, Inc.(ADBT.US)\u8dcc\u5e4526.16%\u3001Stardust Power Inc.(SDST.US)\u8dcc\u5e4522.69%\u3001Polestar Automotive Holding UK PLC Sponsored ADR Class A(PSNY.US)\u8dcc\u5e4520.18%\u3001Research Alliance Corporation III Class A(RACC.US)\u8dcc\u5e4518.99%\u3001\u8fb2\u7c73\u826f\u54c1(FAMI.US)\u8dcc\u5e4518.92%\u3001Aptevo Therapeutics, Inc.(APVO.US)\u8dcc\u5e4518.46%\u3001NetCapital Inc(NCPL.US)\u8dcc\u5e4517.50%\u3002<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u5e8f\u865f<\/th>\n\u4ee3\u78bc<\/th>\n\u540d\u7a31<\/th>\n\u6f32\u8dcc\u5e45(%)<\/th>\n\u6700\u65b0\u50f9<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>\nRARE.US<\/td>\nUltragenyx Pharmaceutical, Inc.<\/td>\n-44.89<\/td>\n14.620<\/td>\n<\/tr>\n
2<\/td>\nGIXI.US<\/td>\nGix Internet Ltd.<\/td>\n-41.50<\/td>\n7.020<\/td>\n<\/tr>\n
3<\/td>\nMDCX.US<\/td>\nMedicus Pharma Ltd<\/td>\n-30.70<\/td>\n0.180<\/td>\n<\/tr>\n
4<\/td>\nADBT.US<\/td>\nAdvasa Holdings, Inc.<\/td>\n-26.16<\/td>\n1.270<\/td>\n<\/tr>\n
5<\/td>\nSDST.US<\/td>\nStardust Power Inc.<\/td>\n-22.69<\/td>\n0.195<\/td>\n<\/tr>\n
6<\/td>\nPSNY.US<\/td>\nPolestar Automotive Holding UK PLC Sponsored ADR Class A<\/td>\n-20.18<\/td>\n9.570<\/td>\n<\/tr>\n
7<\/td>\nRACC.US<\/td>\nResearch Alliance Corporation III Class A<\/td>\n-18.99<\/td>\n16.000<\/td>\n<\/tr>\n
8<\/td>\nFAMI.US<\/td>\n\u8fb2\u7c73\u826f\u54c1<\/td>\n-18.92<\/td>\n0.122<\/td>\n<\/tr>\n
9<\/td>\nAPVO.US<\/td>\nAptevo Therapeutics, Inc.<\/td>\n-18.46<\/td>\n2.120<\/td>\n<\/tr>\n
10<\/td>\nNCPL.US<\/td>\nNetCapital Inc<\/td>\n-17.50<\/td>\n0.850<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

(\u6765\u6e90:\u8d22\u534e\u793e) <\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n

Ultragenyx Pharmaceutical<\/a> Inc.<\/a> Gix Internet Ltd.<\/a> Medicus Pharma Ltd<\/a> Advasa Holdings<\/a> Inc.<\/a> Stardust Power Inc.<\/a> Polestar Automotive Holding UK PLC Sponsored ADR Class A<\/a> Research Alliance Corporation III Class A<\/a> \u8fb2\u7c73\u826f\u54c1<\/a> Aptevo Therapeutics<\/a> Inc.<\/a> NetCapital Inc<\/a> <\/div>\n
\n
\"\u7f8e\u80a1\u8dcc\u5e45\u699c\u524d\u5341\uff0cUltragenyx <\/a> <\/div>\n<\/div>\n
<\/div>\n
\n
\n

\u4e0a\u4e00\u7bc7\u65b0\u805e<\/h3>\n

\u9999\u6e2f\u8b49\u76e3\u6703\uff1a\u52a0\u5f37\u8a8d\u53ef\u57fa\u91d1\u5c31\u79c1\u52df\u5e02\u5834\u8cc7\u7522\u6295\u8cc7\u7684\u6307\u5f15<\/a> <\/div>\n

<\/div>\n<\/p><\/div>\n
\n

\u76f8\u95dc\u6587\u7ae0<\/h3>\n
\n
4\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u9999\u6e2f\u8b49\u76e3\u6703\uff1a\u52a0\u5f37\u8a8d\u53ef\u57fa\u91d1\u5c31\u79c1\u52df\u5e02\u5834\u8cc7\u7522\u6295\u8cc7\u7684\u6307\u5f15<\/a><\/dd>\n
5\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u5fa9\u661f\u91ab\u85e5(600196.SH)\u63a7\u80a1\u5b50\u516c\u53f8\u8606\u6c83\u7f8e\u66ff\u5c3c\u7247\u65b0\u589e\u9069\u61c9\u75c7\u7372\u8a3b\u518a\u6279\u51c6<\/a><\/dd>\n
5\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u3010\u7570\u52d5\u80a1\u3011\u6e2f\u80a1\u8dcc\u5e45\u699c\u524d\u5341\uff0c\u4e2d\u570b\u6578\u667a\u79d1\u6280(01796.HK)\u8dcc32.52%\uff0c\u4e2d\u570b\u6578\u5b57\u8996\u983b(08280.HK)\u8dcc26.32%<\/a><\/dd>\n
5\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u3010\u7570\u52d5\u80a1\u3011\u6e2f\u80a1\u6f32\u5e45\u699c\u524d\u5341\uff0c\u5104\u9054\u4e2d\u570b(03639.HK)\u6f32+42.86%\uff0c\u9ad8\u5730\u80a1\u4efd(01676.HK)\u6f32+38.78%<\/a><\/dd>\n
13\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u5609\u85dd\u63a7\u80a1(01025.HK)\u5fa9\u724c<\/a><\/dd>\n
13\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u667a\u4e2d\u570b\u969b(06063.HK)\u505c\u724c<\/a><\/dd>\n
17\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u77e5\u540d\u7f8e\u80a1\u8dcc\u5e45\u699c\u524d\u5341\uff0cPalo Alto Networks, Inc.(PANW.US)\u8dcc9.28%\uff0c\u6cd5\u62c9\u7b2c\u672a\u4f86(FFAI.US)\u8dcc9.00%<\/a><\/dd>\n
17\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u77e5\u540d\u7f8e\u80a1\u6f32\u5e45\u699c\u524d\u5341\uff0c\u6234\u723e\u79d1\u6280-C(DELL.US)\u6f32+15.81%\uff0cDefinitive Healthcare Corp. Class A(DH.US)\u6f32+15.26%<\/a><\/dd>\n
17\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u4e2d\u6982\u80a1\u8dcc\u5e45\u699c\u524d\u5341\uff0cWetour Robotics Limited(WETO.US)\u8dcc33.84%\uff0c\u78b3\u535a\u58eb\u63a7\u80a1(TANH.US)\u8dcc32.34%<\/a><\/dd>\n
17\u5c0f\u6642\u524d
<\/span><\/dt>\n
\u4e2d\u6982\u80a1\u6f32\u5e45\u699c\u524d\u5341\uff0c\u96f2\u7c73(VIOT.US)\u6f32+83.64%\uff0c\u7d22\u5a01\u723e(LHSW.US)\u6f32+28.82%<\/a><\/dd>\n<\/dl><\/div>\n","protected":false},"excerpt":{"rendered":"

\u65e5\u671f\uff1a 2026\u5e749\u67083\u65e5 \u4e0b\u53489:45 \u3010\u8ca1\u83ef\u793e\u8a0a\u3011\u5317\u4eac\u6642\u95932026\u5e749\u670803\u65e5\u665a\u9593\uff0c\u7f8e\u80a1\u5468\u56db\u65e9\u76e4\uff0c\u7f8e\u80a1\u8dcc\u5e45 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[258,95],"views":25,"_links":{"self":[{"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=\/wp\/v2\/posts\/840168"}],"collection":[{"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=840168"}],"version-history":[{"count":0,"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=\/wp\/v2\/posts\/840168\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=840168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=840168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alphaseek.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=840168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}